1. Predictive factors of response to mTOR inhibitors in neuroendocrine tumours
- Author
-
Zatelli, Maria Chiara, Fanciulli, Giuseppe, Malandrino, Pasqualino, NIKE GROUP: Albertelli M, Arvat E, Baldelli R, Berruti A, Bianchi A, Bodei L, Botti G, Corcione F, Daví MV, Delle Fave G, De Marinis L, Di Sarno A, Dicitore A, Fazio N, Ferolla P, Ferone D, Filice A, Gallo M, Giordano C, Giuffrida D, Guarnotta V, Lania A, Lastoria S, Logoluso F, Loli P, Manzoni M, Marchetti M, Martini C, Messina E, Modica R, Motta C, Papotti M, Partelli S, Persico G, Pia A, Piovesan A, Pontecorvi A, Razzore P, Rota F, Scavuzzo F, Sciammarella C, Vitale G., RAMUNDO, VALERIA, FAGGIANO, ANTONGIULIO, COLAO, ANNAMARIA, DE ROSA, GAETANO, Zatelli, M, Fanciulli, G, Malandrino, P, Ramundo, V, Faggiano, A, Colao, A, Giordano, C, Zatelli, Mc, Nike, Group, Partelli, S, Zatelli, Maria Chiara, Fanciulli, Giuseppe, Malandrino, Pasqualino, Ramundo, Valeria, Faggiano, Antongiulio, Colao, Annamaria, NIKE GROUP: Albertelli, M, Arvat, E, Baldelli, R, Berruti, A, Bianchi, A, Bodei, L, Botti, G, Corcione, F, Daví, Mv, Delle Fave, G, De Marinis, L, DE ROSA, Gaetano, Di Sarno, A, Dicitore, A, Fazio, N, Ferolla, P, Ferone, D, Filice, A, Gallo, M, Giuffrida, D, Guarnotta, V, Lania, A, Lastoria, S, Logoluso, F, Loli, P, Manzoni, M, Marchetti, M, Martini, C, Messina, E, Modica, R, Motta, C, Papotti, M, Persico, G, Pia, A, Piovesan, A, Pontecorvi, A, Razzore, P, Rota, F, Scavuzzo, F, Sciammarella, C, and Vitale, G.
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,mTOR inhibitor ,Endocrinology, Diabetes and Metabolism ,Neuroendocrine tumors ,Antineoplastic Agent ,0302 clinical medicine ,Endocrinology ,Neuroendocrine tumours ,neuroendocrine tumour ,Treatment resistance ,MTOR inhibitors ,Tumor ,Medical treatment ,TOR Serine-Threonine Kinases ,Discovery and development of mTOR inhibitors ,Response to treatment ,Patient management ,Diabetes and Metabolism ,Neuroendocrine Tumors ,030220 oncology & carcinogenesis ,Neuroendocrine Tumor ,Human ,Predictors ,Animals ,Antineoplastic Agents ,Biomarkers, Tumor ,Diagnostic Imaging ,Humans ,Protein Kinase Inhibitors ,medicine.medical_specialty ,Protein Kinase Inhibitor ,Early detection ,predictor ,Biology ,NO ,03 medical and health sciences ,mTOR inhibitors ,neuroendocrine tumours ,predictors ,response to treatment ,Internal medicine ,medicine ,mTOR inhibitors,neuroendocrine tumours,predictors,response to treatment ,mTOR inhibitors, neuroendocrine tumours, predictors, response to treatment ,Animal ,medicine.disease ,030104 developmental biology ,Immunology ,Biomarkers ,Resource utilization - Abstract
Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for therapeutic response are under intensive investigation, aiming at a tailored patient management and more appropriate resource utilization. This review summarizes the available data on the tissue, circulating and imaging markers that are potentially predictive of rapalog efficacy in NETs.
- Published
- 2015
- Full Text
- View/download PDF